1. Home
  2. SKE vs CRSP Comparison

SKE vs CRSP Comparison

Compare SKE & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skeena Resources Limited

SKE

Skeena Resources Limited

SELL

Current Price

$29.94

Market Cap

4.4B

ML Signal

SELL

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

SELL

Current Price

$50.20

Market Cap

5.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SKE
CRSP
Founded
1979
2013
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.2B
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
SKE
CRSP
Price
$29.94
$50.20
Analyst Decision
Strong Buy
Buy
Analyst Count
5
22
Target Price
$39.84
★ $87.50
AVG Volume (30 Days)
426.0K
★ 1.7M
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $289,590,000.00
Revenue This Year
N/A
$1,063.30
Revenue Next Year
N/A
$283.48
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 9169.85
52 Week Low
$15.43
$44.12
52 Week High
$38.77
$75.06

Technical Indicators

Market Signals
Indicator
SKE
CRSP
Relative Strength Index (RSI) 43.98 39.88
Support Level $28.54 $45.61
Resistance Level $34.20 $60.71
Average True Range (ATR) 1.06 2.62
MACD 0.05 -0.60
Stochastic Oscillator 15.25 9.98

Price Performance

Historical Comparison
SKE
CRSP

About SKE Skeena Resources Limited

Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: